Increased serum concentration of netrin-1 after intravitreal bevacizumab injection: is it a compensatory mechanism to counteract drug side effects?

Table 5 Correlation table showing the changes between vascular endothelial growth factor and netrin-1 concentrations, the logarithm of the minimum angle of resolution, and cube average thickness differences at one month post-bevacizumab injection in the non-proliferative diabetic retinopathy and proliferative diabetic retinopathy groups

				1 month netrin-1 difference	1 month VEGF difference	1 month VA (LogMAR) difference	1 month CAT (μm) difference
Spearman’s rho	NPDR Group	1 month netrin-1 difference	r	1.000	−0.685^a	0.257	0.418
			p	.	0.029	0.474	0.229
			N	10	10	10	10
		1 month VEGF difference	r	−0.685^*	1.000	−0.416	0.079
			p	0.029	.	0.232	0.829
			N	10	10	10	10
	PDR Group	1 month netrin-1 difference	r	1.000	−0.341	0.061	0.118
			p	.	0.255	0.842	0.700
			N	13	13	13	13
		1 month VEGF difference	r	−0.341	1.000	0.237	−0.066
			p	0.255	.	0.435	0.830
			N	13	13	13	13

^a Correlation is significant at the 0.05 level (2-tailed)
VA Visual acuity, LogMAR The logarithm of the minimum resolution angle, CAT Cube average thickness, NPDR Non-proliferative diabetic retinopathy, PDR Proliferative diabetic retinopathy, VEGF Vascular endothelial growth factor. r: Correlation Coefficient

ISSN: 1471-2415